Biosens develops point-of-care diagnostic solutions utilizing biosensors, Graphene, Single-Domain Antibodies, and CRISPR technologies for rapid and accurate testing. This approach enhances patient outcomes and reduces healthcare costs by enabling timely diagnosis at the site of care.
Funding
$870K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional diagnostic testing often requires sending samples to centralized labs, leading to delays in obtaining results and initiating treatment. This can be particularly problematic in point-of-care settings where rapid diagnosis is critical for effective patient management.
Solution
Biosens develops point-of-care diagnostic solutions that enable rapid and accurate testing at the site of care. The company leverages biosensors, graphene, single-domain antibodies, and CRISPR technologies to create diagnostic tools that deliver timely results. By providing healthcare professionals with access to rapid diagnostic information, Biosens aims to improve patient outcomes and reduce healthcare costs associated with delayed diagnoses. Their solutions empower healthcare providers to make informed decisions quickly, leading to more effective treatment plans and improved patient care.
Target Audience
The primary target audience includes healthcare professionals and patients who require rapid and accurate diagnostic testing at the point of care.
Features
- Utilizes biosensors for rapid detection of target analytes.
- Employs graphene to enhance sensor sensitivity and performance.
- Leverages single-domain antibodies for highly specific target recognition.
- Integrates CRISPR technology for advanced diagnostic capabilities.